A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes

Inclusion Criteria: * The subject has a 6 month diagnosis of Type 2 diabetes mellitus prior to screening and meets the American Diabetes Association (ADA) guidelines for Type 2 diabetes mellitus. * On a stable regimen of metformin monotherapy equivalent to at least 1000 mg/day for the last 3 months prior to screening. * Males. Females of non-childbearing potential. * Generally stable health without a history of major surgery or significant injuries within the last year and without an active infection. Exclusion Criteria: * Diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young, insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus, or history of diabetic ketoacidosis. * Participation in a clinical trial and receipt of an investigational product within 30 days. * Participation in any formal weight loss program, or fluctuation of \> 5% in body weight, or having received medications approved for weight loss within 3 months prior to screening or contemplating such therapy during the trial. * Previous surgical treatment of obesity. * Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice administered by someone other than the patient within 6 months prior to screening. * Use of other diabetic agents except metformin within 3 months prior to Screening. * History of pancreatitis. * Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to screening. * History of hemolytic anemia, chronic transfusion requirement or other condition rendering HbA1c results unreliable. * History of MEN-2 or family history of medullary thyroid cancer. * History or presence of clinically significant disease (other than Type 2 diabetes mellitus).